Analysts Expect Acceleron Pharma Inc. (XLRN) Will Announce Earnings of -$0.61 Per Share
Equities research analysts predict that Acceleron Pharma Inc. (NASDAQ:XLRN) will announce earnings per share of ($0.61) for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Acceleron Pharma’s earnings. The highest EPS estimate is ($0.57) and the lowest is ($0.68). Acceleron Pharma reported earnings of ($0.51) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 19.6%. The company is expected to report its next earnings results on Wednesday, March 7th.
On average, analysts expect that Acceleron Pharma will report full year earnings of ($2.67) per share for the current financial year, with EPS estimates ranging from ($2.76) to ($2.60). For the next year, analysts expect that the company will report earnings of ($2.41) per share, with EPS estimates ranging from ($2.61) to ($2.19). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm had revenue of $3.00 million for the quarter, compared to the consensus estimate of $3.52 million. During the same quarter last year, the business posted ($0.55) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year.
Several brokerages have weighed in on XLRN. Royal Bank Of Canada began coverage on Acceleron Pharma in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $44.00 target price on the stock. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a research note on Wednesday, September 20th. Barclays lifted their target price on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday, September 20th. HC Wainwright initiated coverage on Acceleron Pharma in a research note on Thursday, October 12th. They issued a “buy” rating and a $57.00 target price on the stock. Finally, Cann reissued a “hold” rating on shares of Acceleron Pharma in a report on Tuesday, September 5th. Two research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Acceleron Pharma presently has a consensus rating of “Buy” and an average target price of $44.56.
Shares of Acceleron Pharma (NASDAQ XLRN) traded down $0.73 during mid-day trading on Friday, hitting $34.81. The company’s stock had a trading volume of 344,682 shares, compared to its average volume of 385,207. Acceleron Pharma has a one year low of $23.07 and a one year high of $40.35.
In other news, EVP Matthew L. Sherman sold 18,400 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $38.41, for a total value of $706,744.00. Following the completion of the sale, the executive vice president now directly owns 79,750 shares of the company’s stock, valued at approximately $3,063,197.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP John D. Quisel sold 5,113 shares of the firm’s stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $38.42, for a total value of $196,441.46. Following the completion of the sale, the senior vice president now directly owns 57,918 shares of the company’s stock, valued at $2,225,209.56. The disclosure for this sale can be found here. Insiders sold a total of 53,513 shares of company stock valued at $2,055,485 over the last three months. Insiders own 3.90% of the company’s stock.
A number of hedge funds have recently modified their holdings of XLRN. Perceptive Advisors LLC raised its holdings in Acceleron Pharma by 127.2% during the third quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock worth $60,319,000 after purchasing an additional 905,000 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in Acceleron Pharma by 46.6% during the second quarter. Westfield Capital Management Co. LP now owns 1,682,359 shares of the biopharmaceutical company’s stock worth $51,127,000 after purchasing an additional 534,440 shares during the last quarter. Sectoral Asset Management Inc raised its holdings in Acceleron Pharma by 378.2% during the second quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock worth $18,371,000 after purchasing an additional 478,099 shares during the last quarter. BlackRock Inc. raised its holdings in Acceleron Pharma by 9.0% during the second quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock worth $121,719,000 after purchasing an additional 330,635 shares during the last quarter. Finally, AXA acquired a new position in Acceleron Pharma during the second quarter worth $9,833,000. 85.84% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: This story was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark law. The legal version of this story can be viewed at https://theolympiareport.com/2017/12/04/analysts-expect-acceleron-pharma-inc-xlrn-will-announce-earnings-of-0-61-per-share.html.
About Acceleron Pharma
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acceleron Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.